Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Apple Turns 50: From Garage Startup to AI Crossroads 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Britain Courts Anthropic Amid US Defense Department Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
CAMBRIDGE, Mass., Sept. 26, 2016 -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held in New York City on September 27, 2016.
| Ladenburg Thalmann 2016 Healthcare Conference | |
| Date: | Tuesday, September 27 |
| Time: | 11:30am Eastern Time |
| Location: | Sofitel Hotel New York, Odeon Room |
| Webcast: | http://wsw.com/webcast/ladenburg2/clcd |
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
